Corcept Therapeutics declines due to missed revenue expectations and weak guidance

LootboxPhobia · 2026-02-25T10:37:29+00:00

Corcept Therapeutics' Q4 performance fell short of expectations, with revenue of $202.1 million and earnings per share of $0.20, both below analyst estimates, primarily due to operational disruptions. Despite a 37% increase in tablet sales, earlier supplier issues still led to a decline in performance. The company projects revenue guidance for fiscal year 2026 to be between $900 million and $1 billion.

LootboxPhobia

2026-02-25 10:37:29

Abstract generation in progress

Investing.com – Corcept Therapeutics Incorporated (NASDAQ:CORT) reported fourth-quarter results that fell short of Wall Street expectations due to operational disruptions affecting performance, with both profits and revenue below analyst estimates.

The company’s fourth-quarter revenue was $202.1 million, below the consensus estimate of $249.5 million, but up 11% from $181.9 million in the same period last year. Adjusted earnings per share were $0.20, below the estimated $0.25. Full-year revenue for 2025 reached $761.4 million, up from $675 million in 2024.

After-hours trading on Tuesday saw the stock decline by 5.4%.

Corcept attributed the underperformance to capacity constraints from its former specialty pharmacy supplier and operational disruptions during the transition to new specialty pharmacies in the fourth quarter. Despite these challenges, the company reported a 37% increase in tablet sales compared to last year, with record numbers of new prescriptions and prescribing physicians in 2025.

CEO Joseph K. Belanoff stated, “We should have achieved higher growth, but capacity limitations from our former specialty pharmacy supplier prevented us from fully meeting demand. This transition is now complete, and February is expected to be a record month for new patients starting treatment with our medication.”

Corcept’s guidance for fiscal year 2026 revenue is between $900 million and $1 billion. The midpoint of $950 million is slightly below the analyst consensus of $960 million.

The company reported net income of $99.7 million for 2025, with diluted earnings per share of $0.82, compared to net income of $141.2 million and earnings per share of $1.23 in 2024. As of December 31, 2025, cash and investments totaled $532.4 million.

Corcept continues to collaborate with the FDA on a new drug application for relacorilant to treat Cushing’s syndrome, with a PDUFA date set for July 11, 2026.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes